ReviewBiomarker research2026
tRNA modifications in cancer: from molecular mechanisms to clinical translation.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Molecular cancer · 2026Review
- Gut microbiota dysbiosis in COPD patients increases the level of queuine in the blood serum abnormally enhancing the viability of lung epithelial cells.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
tRNA modifications, the most extensively and diversely modified class of RNA across all domains of life, have garnered significant and growing attention in research over the past decade. tRNA modification defects and tRNA fragmentation has been observed within a wide spectrum of cancer types, suggesting their potential as diagnostic and prognostic biomarkers. Mechanistic studies demonstrate that regulatory enzymes for tRNAs and tdRs function as oncogenes or tumor suppressors with vital roles in cancer initiation, progression, metastasis, metabolic rewiring, therapy resistance, and immune evasion, highlighting the therapeutic potential of targeting perturbed tRNA modification machinery in cancer treatment. Herein, we summarize our current understanding of the role of tRNA modifications in cancer, and outline translational and clinical implications for cancer diagnosis and treatment. Emphasis is placed on how tRNA modifications determine the fate of target tRNAs and its influence on protein expression, molecular mechanisms and cell phenotypes. Finally, we discuss the hurdles and potential solutions to translating recent knowledge of tRNA modifications into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.